DOI: https://doi.org/10.22141/2224-0721.0.2.42.2012.176864

Possibilities of Alpha-lipoic Acid Use in Treatment of Diabetes Mellitus Complications in Children and Adolescents

O.V. Bolshova, O.Ya. Samson

Abstract


The article deals with one of most common complications of diabetes mellitus — diabetic polyneuropathy. It is proved that alpha-lipoic acid is a drug of pathogenetic treatment of such pathology. Through the example of study of 100 patients with diabetes mellitus there was shown the efficacy of alpha-lipoic acid drug Berlithion at diabetic polyneuropathy in children and
adolescents.


Keywords


diabetes mellitus, polyneuropathy, alpha-lipoic acid, Berlithion, children, adolescents

References


American Diabetes Association, American Academy of Neurology: Report and recommendations of the San Antonio Conference on Diabetic Neuropathy (Consensus Statement) // Diab. Care. — 1988. — Vol. 11. — P. 592-597.

Boulton A.J.M. et al. Diabetic somatic neuropathies // Diab. Care. — 2004. — Vol. 27. — P. 1458-1486.

Boulton A.J.M. et al. Diabetic neuropathies: a statement by the American Diabetes Association // Diab. Care — 2005. — Vol. 28. — P. 956-962.

Wang Y. et al. Enhanced inflammatory response via activation of NF-kappaB in acute experimental diabetic neuropathy subjected to ischemia-reperfusion injury // J. Neurol. Sci. — 2006. — Vol. 15. — P. 47-52.

Coppini D.V., Bowtell P.A., Weng C. et al. Showing neuropathy is related to increased mortality in diabetic patients: a survival analysis using an accelerated failure time model // J. Clin. Epidemiol. — 2000. — Vol. 53. — P. 519-523.

Dyck P.J., Dyck P.J.B. Diabetic polyneuropathy: section III // Diabetic Neuropathy / Eds. P.J. Dyck, P.K. Thomas. — 2nd ed. — Philadelphia: W.B. Saunders, 1999. — P. 255-278.

Sundkvist G. et al. Sorbitol and myo-inositol levels and morphology of sural nerve in relation to peripheral nerve function and clinical neuropathy in men with diabetic, impaired, and normal glucose tolerance // Diab. Med — 2000. — Vol. 17. — P. 259-268.

Over D.S. et al. Quantitative assessment of diabetic peripheral neuropathy with use of the clanging tuning fork test // Endocr Pract. — 2007. — Vol. 13. — P. 5-10.

Satish K. et al. Role of Aldose Reductase and Oxidative Damage in Diabetes and the Consequent Potential for Therapeutic Options. First published online on April 6, 2005 // Endocrine Reviews doi:10.1210/er. 2004-0028.

Sima A.A.F., Sugimoto K. Experimental diabetic neuropathy: an update // Diabetologia. — Vol. 42. — P. 773-788.

Breqovski V.B. et al. Predictors of alpha-lipoic acid treatment efficacy in diabetic polyneuropathy of the lower limbs // Ter. Arkh. — 2005. — Vol. 77. — P. 15-19.

Jude E.B., Boulton A.J.M. End-stage complications of diabetic neuropathy // Diab. Rev. — 1999. — Vol. 7. — P. 395-410.

Ametov A.S., Barinov A., Dyck P.J. et al. SYDNEY Trial Study Group: The sensory symptoms of diabetic polyneuropathy are improved with a-lipoic acid: the SYDNEY trial // Diab. Care. — 2003. — Vol. 26. — P. 770-776.

Nagamatsu M. Lipoic acid improves distal nerve blood flow, reduces oxidative stress and improves distal nerve conduction in experimental diabetic neuropathy // Diabetes. — 2000. — Vol. 49. — P. 1006-1015.

Ruhnau K.J. et al. Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy // Diab. Med. — 1999. — Vol. 16. — P. 1040-1043.

Tanq J. et al. Alpha-lipoic acid may improve symptomatic diabetic polyneuropathy // Neurologist. — 2007. — Vol. 13. — P. 164-167.

Shaw J.E. et al. Epidemiology of diabetic neuropathy // Textbook of Diabetic Neuropathy / Eds. F.A. Gries, N.E. Cameron, P.A. Low, D. Ziegler. — New York: Thieme, 2003. — P. 64-82

Ziegler D., Hanefeld M., Ruhnau K.J. et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study) // Diabetologia. — 1995. — Vol. 38(12). — P. 1425-1433.

Reljanovic M., Reichel G., Rett K. et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy // Free Radic. Res. — 1999. — Vol. 31(3). — P. 171-179.

Ziegler D., Hanefeld M., Ruhnau K.J. et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy // Diabetes Care. — 1999. — Vol. 22 (8). — P. 1296-1301.

Ziegler D., Schatz H., Conrad F. et al. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie // Diabetes Care. — 1997 Mar. — 20(3). — 369-73.

Ruhnau K.J., Meissner H.P., Finn J.R., Reljanovic M., Lobisch M., Schütte K., Nehrdich D., Tritschler H.J., Mehnert H., Ziegler D. Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy // Diabet Med. — 1999. — Vol. 16(12). — P. 1040-1043.

Ametov A.S., Barinov A., Dyck P. et al. SYDNEY Trial Study Group.The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial // Diabetes Care. — 2003. — Vol. 26 (3). — P. 770-776.






Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2019

 

   Seo анализ сайта